News

A new therapeutic agent may offer hope to young people suffering from a severe form of muscle cancer. As a research team led by Anton Henssen reports in “Nature Communications”, this agent prevents the repair of DNA damage in cancer cells, ultimately causing their death.

With its "Back to the roots" Lab, the Max Delbrück Center aims to enable young international researchers to become ambassadors for Research in Germany in their home countries. It is one of the winners of the DFG Community Prize.

BRCA1/2-mutated tumor cells often survive treatment, whether it’s chemo- or radiotherapy, because they can repair therapy-induced DNA damage. A team led by Claus Scheidereit of the Max Delbrück Center has now reported in The EMBO Journal how blocking the TSG101 protein hinders these tumor cells from carrying out repair processes.

The newly appointed scientific director of the Max Delbrück Center is recognized for her pioneering stem cell work in diabetes. Her team studies the development and function of insulin-producing beta cells and aims to generate beta cells from stem cells, paving the way for therapeutic applications.

If a secretion in the lungs’ alveoli is not cleared regularly, breathing difficulties can develop. In a study published in Science Immunology, a team led by Alexander Mildner and Achim Leutz has now explained the pivotal role of the transcription factor C/EBPb in this process.

Two artworks by sculptor Anna Franziska Schwarzbach have been unveiled at the Berlin-Buch campus to honor two outstanding women scientists of the 20th century. This special occasion, timed to coincide with the 119th birthday of the elder sister, Marthe Vogt, also marked the launch of the new CAMPUSart project.

Klaus Rajewsky’s life reads like a chronicle of immunogenetics. He grasped the opportunities offered by radical changes in molecular biology. He established standard methods for researching gene functions and diseases like cancer. And he continues to contribute to our understanding of antibody-producing B cells.

Their name rarely appears on a paper. And yet, without them there would be no publications: Staff members who work in the background to ensure that research runs smoothly at the Max Delbrück Center. Every year at the summer party, the most dedicated among them are honored with the Silent Hero Award.

MyoPax, a new spin-off of the Max Delbrück Center and Charité, receives a 1.3 million euros loan to jump-start its entrepreneurial activities. The start-up develops regenerative therapies for previously incurable muscle diseases using its innovative muscle stem cell technology.

What role do a common receptor and diet play in chronic inflammation? That is the question that the Experimental and Clinical Research Center (ECRC) and other partners will pursue over the next three years in a consortium project funded by the BMBF.